Last updated: September 5, 2026
Oxymorphone hydrochloride is a small, declining opioid market with limited commercial scale. The branded franchise, led by Endo Pharmaceuticals’ Opana and Opana ER, lost most of its value after generic competition, opioid-policy restrictions, and FDA action against Opana ER. Current demand is concentrated in a narrow generic market for immediate-release tablets, with limited manufacturer participation, controlled-substance compliance costs, and weak growth prospects.
Public filings do not report a standalone, current global revenue figure for oxymorphone hydrochloride. The clearest financial pattern is the collapse of branded extended-release sales after Endo withdrew Opana ER in 2017, followed by a low-value generic market with limited public disclosure.
What is the current market status of oxymorphone hydrochloride?
Oxymorphone hydrochloride is a Schedule II opioid analgesic used for severe acute and chronic pain. It is marketed primarily as an immediate-release oral tablet in generic form. The former branded products were:
| Product |
Formulation |
Historical sponsor |
Current commercial position |
| Opana |
Immediate-release tablets |
Endo Pharmaceuticals |
Brand largely displaced by generics |
| Opana ER |
Extended-release tablets |
Endo Pharmaceuticals |
Withdrawn from the U.S. market in 2017 |
| Generic oxymorphone hydrochloride |
Immediate-release tablets |
Multiple ANDA sponsors over time |
Limited, regulated generic market |
| Generic extended-release oxymorphone |
Extended-release tablets |
Various approved ANDA sponsors |
Commercial availability substantially reduced after brand withdrawal and opioid-market contraction |
The product has a narrow addressable market because prescribers and payers have shifted toward non-opioid treatments, buprenorphine, abuse-deterrent products, and lower-cost conventional opioids. State prescribing limits, opioid monitoring programs, prior authorization, and tighter pharmacy controls have reduced utilization across the category.
How large is the oxymorphone hydrochloride market?
No current public filing provides a reliable standalone market-size estimate for all oxymorphone hydrochloride products. Public company disclosures generally aggregate oxymorphone with broader pain portfolios or do not separately identify the product.
The market can be characterized by three financial phases:
| Period |
Market phase |
Financial driver |
| Before 2012 |
Branded growth and premium pricing |
Opana and Opana ER held branded market share |
| 2012-2016 |
Generic and regulatory erosion |
Generic entry, opioid scrutiny, and reformulation disputes reduced value |
| 2017 onward |
Post-brand contraction |
Opana ER withdrawal eliminated the primary branded revenue stream |
Endo reported material Opana-related sales before withdrawal. Opana ER net sales were approximately $165 million in 2016, according to Endo’s 2016 annual report. The product’s withdrawal in 2017 removed a major contributor to Endo’s pain franchise and accelerated the transition to a low-margin generic market.
The current market is likely measured in a small fraction of historical branded sales, although exact global revenue cannot be established from public sources. Generic oxymorphone hydrochloride is not a major revenue product for the large pharmaceutical manufacturers that report opioid sales separately.
When did Opana ER lose exclusivity and commercial value?
Opana ER lost effective commercial exclusivity through a combination of patent challenges, generic competition, and regulatory action rather than through a single event.
Key exclusivity and regulatory timeline
| Date |
Event |
Commercial effect |
| 2006 |
FDA approval of Opana ER |
Established Endo’s extended-release oxymorphone franchise |
| 2011-2012 |
Generic challenges and litigation involving extended-release oxymorphone |
Created launch risk and restricted long-term exclusivity |
| 2012 |
Endo introduced a reformulated, crush-resistant version of Opana ER |
Attempted to protect the product from manipulation and preserve demand |
| 2013-2016 |
Continued opioid-abuse scrutiny and litigation |
Increased regulatory and reputational pressure |
| June 2017 |
FDA requested withdrawal of Opana ER from the market |
Endo discontinued the product |
| 2018 |
FDA determined that Opana ER was withdrawn for reasons of safety or effectiveness |
Limited the ability to use the withdrawn product as a reference for certain generic approvals |
FDA’s 2017 action was based on the agency’s conclusion that the public-health risks associated with abuse by injection outweighed the product’s benefits. Endo announced the withdrawal shortly afterward. The action ended the remaining branded commercial opportunity for Opana ER in the United States. [1]
What is the FDA and Orange Book status of oxymorphone hydrochloride?
The FDA status differs between immediate-release generic tablets and extended-release products.
Immediate-release tablets
Generic immediate-release oxymorphone hydrochloride tablets have historically been approved through abbreviated new drug applications. These products rely on pharmaceutical equivalence and bioequivalence to the relevant reference product.
The immediate-release market remains legally viable, but commercial participation is constrained by:
- Schedule II controlled-substance requirements
- DEA manufacturing and distribution quotas
- Opioid supply-chain controls
- Pharmacist and wholesaler scrutiny
- Limited demand
- Potential manufacturing and compliance costs that are high relative to sales
Extended-release products
Opana ER was discontinued and was not simply a routine commercial discontinuation. FDA determined that it was withdrawn for safety or effectiveness reasons. That distinction is important because a product withdrawn for safety or effectiveness generally cannot be used as an ordinary reference product for a new ANDA pathway. [2]
The FDA Orange Book should be reviewed for the current listing status of specific oxymorphone products, patents, and exclusivity entries. Historical Orange Book listings for Opana ER included formulation and method-of-use protections, but the commercial value of those rights declined sharply after the FDA withdrawal.
What patents protected Opana and Opana ER?
The Opana patent estate historically included claims covering oxymorphone compositions, extended-release formulations, dosage forms, and methods of treating pain. The most commercially significant rights were formulation patents directed to sustained or controlled release rather than the underlying oxymorphone molecule alone.
The core product-level patent strategy included:
- Extended-release matrix or dosage-form technology.
- Controlled release of oxymorphone over a defined period.
- Tablet compositions and manufacturing processes.
- Abuse-deterrent or crush-resistant formulations.
- Method-of-use claims for treatment of moderate-to-severe pain.
The commercial value of these patents depended on maintaining an FDA-approved reference product and preventing ANDA substitution. Once Opana ER was removed from the market, the economic value of the remaining formulation estate fell substantially.
A complete current patent opinion requires a live review of the FDA Orange Book, USPTO Patent Center, terminal disclaimers, patent maintenance records, and litigation dockets. Patent expiration dates cannot be stated reliably as a single date because separate formulation, process, and method-of-use patents had different terms and filing dates.
How strong is the oxymorphone hydrochloride patent estate?
The patent estate is commercially weak today for four reasons.
The active ingredient is old
Oxymorphone was known well before the modern commercial products. Any original composition-of-matter protection is long expired. Current rights therefore depend primarily on formulation, manufacturing, or use claims.
Generic substitution is established
Immediate-release tablets have historically been subject to ANDA competition. That makes it difficult to preserve premium pricing through brand-level exclusivity.
The extended-release franchise lost its reference product
The FDA withdrawal of Opana ER weakened the practical value of patents directed to the product. A patent may remain legally unexpired while losing its ability to generate meaningful revenue.
Method-of-use claims have limited enforcement value
Pain-treatment method claims can be difficult to enforce against generic manufacturers because labels, prescribing behavior, and actual use may create complex infringement questions. This is especially true for a product with a declining and highly controlled market.
Overall, the estate has residual legal relevance but limited current commercial leverage.
Which companies challenged Opana ER patents?
Historical patent challenges involved generic manufacturers seeking approval to market extended-release oxymorphone tablets. Publicly reported litigation and regulatory activity associated with the Opana ER franchise involved Endo and generic pharmaceutical companies, including Actavis and other ANDA applicants.
The commercial effect of these challenges was significant even where litigation did not produce an immediate generic launch. Paragraph IV certifications can force patent litigation, create settlement negotiations, and reduce the expected duration of branded exclusivity.
Because the product was later withdrawn for safety reasons, the economic importance of historical Paragraph IV litigation is now primarily analytical. It explains the erosion of the franchise but does not create a current branded market.
What was the impact of Opana ER’s reformulation?
Endo reformulated Opana ER in 2012 to make the tablets more difficult to crush and manipulate. The reformulation was intended to reduce abuse by injection and preserve the product’s clinical and commercial position.
The strategy did not eliminate regulatory risk. FDA later concluded that the reformulated product still presented an abuse risk, particularly through injection. In 2017, the agency requested withdrawal after reviewing postmarketing evidence and public-health concerns. [1]
The reformulation created three consequences:
- It added manufacturing complexity.
- It generated new formulation and regulatory issues.
- It failed to preserve the product’s U.S. commercial authorization.
The episode shows that abuse-deterrent design can extend product differentiation only if regulators accept that the formulation produces a meaningful public-health benefit.
Does oxymorphone hydrochloride face biosimilar competition?
No. Oxymorphone hydrochloride is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply.
The relevant competitive pathways are:
- ANDA generic competition
- Authorized generic supply
- Formulation-specific generic approvals
- Competing opioid products
- Non-opioid analgesics
- Abuse-deterrent opioid formulations
- Specialty pain treatments
The principal market threat is therefore generic substitution and therapeutic substitution, not biosimilar entry.
What generic entry risks exist for oxymorphone hydrochloride?
Generic entry risk is high for immediate-release tablets and structurally limited for extended-release products because the original branded extended-release product has been withdrawn.
Immediate-release generic risk
Immediate-release products face:
- Low barriers to pharmaceutical equivalence
- Established prescribing familiarity
- Price-based substitution
- Multiple historical ANDA sponsors
- Low switching costs for pharmacies and payers
The limitation is not legal entry but market economics. A company may obtain approval yet avoid launch because expected sales do not justify controlled-substance compliance, inventory, pharmacovigilance, and distribution costs.
Extended-release generic risk
A conventional commercial generic launch against the former Opana ER franchise is less straightforward after FDA’s safety-based withdrawal determination. The market opportunity is also materially smaller because the reference product no longer provides an active branded platform.
What manufacturing and intellectual-property barriers affect the market?
Oxymorphone manufacturing has a higher compliance burden than ordinary oral solids.
Relevant barriers include:
| Barrier |
Commercial implication |
| DEA quota controls |
Limits production volume and inventory flexibility |
| Controlled-substance security |
Increases facility, logistics, and audit costs |
| API sourcing |
Requires qualified suppliers and regulatory controls |
| Abuse-deterrent formulation technology |
Raises development and validation costs |
| Stability and dissolution testing |
Important for extended-release products |
| Pharmacovigilance |
Requires opioid-specific monitoring |
| Distribution controls |
Restricts wholesalers and pharmacy access |
| Low demand |
Reduces scale economies |
The most defensible intellectual property would relate to a differentiated formulation, a new delivery system, or a clinically accepted abuse-deterrent design. A conventional oxymorphone tablet has limited ability to support premium pricing.
What is the financial trajectory for Endo and the oxymorphone franchise?
Oxymorphone was part of Endo’s broader pain portfolio, but the product’s financial trajectory deteriorated before the franchise ended.
The trajectory was:
- Branded revenue from Opana and Opana ER.
- Pressure from generic competition and opioid-policy changes.
- Investment in reformulation to preserve differentiation.
- FDA withdrawal of Opana ER.
- Elimination of the principal branded revenue stream.
- Residual generic and portfolio value with limited disclosure.
Endo’s 2016 reporting placed Opana ER sales at roughly $165 million. The withdrawal removed that revenue source and reduced the company’s exposure to a product that had become a regulatory liability. The resulting financial impact extended beyond lost sales because the company also faced litigation, restructuring, compliance, and opioid-related legal costs.
For investors, oxymorphone hydrochloride is no longer a growth asset. Its value is linked to small generic sales, supply reliability, and any niche opportunity involving regulated hospital or specialty channels.
How does oxymorphone compare with competing opioids?
| Product |
Market position |
Generic pressure |
Regulatory risk |
Growth outlook |
| Oxymorphone hydrochloride |
Niche opioid |
High |
High |
Declining or flat |
| Oxycodone |
Broad opioid market |
High |
High |
Mature |
| Hydromorphone |
Hospital and specialty use |
High |
High |
Stable niche |
| Morphine |
Large, established generic market |
Very high |
High |
Mature |
| Buprenorphine |
Pain and opioid-use-disorder applications |
High but differentiated by use |
High |
More resilient |
| Fentanyl |
Hospital and specialty applications |
High |
High |
Product-specific |
| Non-opioid analgesics |
Broad substitution alternatives |
Varies |
Lower |
Greater strategic relevance |
Oxymorphone has pharmacologic potency and clinical utility, but those characteristics do not create a strong commercial advantage in a market where payers prioritize cost, regulators prioritize risk controls, and prescribers have multiple alternatives.
What licensing or partnership opportunities exist?
Publicly disclosed licensing activity centered on oxymorphone hydrochloride is limited. The product is unlikely to support a major licensing transaction based solely on conventional tablets.
Potential transaction value would depend on:
- A proprietary abuse-deterrent formulation
- A long-acting injectable or implantable delivery system
- A differentiated hospital product
- A manufacturing advantage
- A secured API supply chain
- A niche international regulatory approval
- A formulation patent with meaningful remaining term
Without one of these characteristics, a transaction would likely be a supply, distribution, or asset-acquisition deal rather than a high-value licensing agreement.
What generic launch scenarios are most likely?
The most likely scenario is continued low-volume generic supply of immediate-release tablets, with periodic manufacturer exits caused by weak margins or compliance costs.
| Scenario |
Probability profile |
Market outcome |
| Stable niche generic supply |
Most commercially plausible |
Low revenue, limited price competition |
| Manufacturer consolidation |
Plausible |
Fewer suppliers and higher shortage risk |
| New branded formulation |
Low |
Requires strong clinical or abuse-deterrent differentiation |
| Broad generic expansion |
Unlikely |
Limited by demand and opioid controls |
| Reintroduction of Opana ER |
Not commercially realistic |
FDA withdrawal and market contraction remain major barriers |
What is the geographic coverage of oxymorphone hydrochloride?
The United States was the most important commercial market for Opana and Opana ER. The product may have regulatory approvals or sales in selected international markets, but the scale is materially smaller and public commercial data are limited.
Geographic expansion faces:
- National controlled-substance rules
- Differing opioid scheduling systems
- Local reimbursement restrictions
- Varying abuse-deterrent requirements
- Limited clinical demand
- Country-specific manufacturing and import controls
The U.S. market remains the central reference point for the product’s commercial history, patent disputes, and regulatory precedent.
Key Takeaways
- Oxymorphone hydrochloride is now a small, mature generic opioid market.
- Endo’s Opana ER franchise lost most of its commercial value after FDA requested withdrawal in 2017.
- Opana ER sales were approximately $165 million in 2016, before withdrawal.
- Immediate-release generic tablets remain the primary commercial form.
- The active ingredient has no meaningful remaining composition-of-matter exclusivity.
- Current patent value is concentrated in formulation, manufacturing, and method-of-use claims.
- Biosimilar competition does not apply because oxymorphone is a small molecule.
- Generic entry risk is high, but actual launches are constrained by low demand and controlled-substance costs.
- A new commercial opportunity would require differentiated delivery technology, abuse deterrence, specialty distribution, or manufacturing advantages.
- The financial outlook is flat to declining, with limited upside absent a new formulation or regulatory pathway.
FAQs
Is oxymorphone hydrochloride still commercially available?
Generic immediate-release oxymorphone hydrochloride tablets have been marketed in the United States, but availability can vary by manufacturer, wholesaler inventory, and controlled-substance supply conditions.
Was Opana ER removed because it was ineffective?
FDA’s action focused on the product’s public-health risks, particularly abuse by injection. The agency determined that the benefits of Opana ER did not outweigh its risks and classified the withdrawal as safety-related. [1][2]
Can a company launch a generic version of Opana ER?
A company would face substantial regulatory and commercial obstacles. FDA’s safety-based withdrawal determination affects the reference-product pathway, while weak demand and opioid controls reduce the economic incentive for development.
Does oxymorphone hydrochloride have an abuse-deterrent patent opportunity?
Potentially, but the opportunity would depend on a demonstrable formulation advantage, valid patent claims, FDA acceptance, and evidence that the technology reduces clinically relevant abuse. A conventional extended-release formulation would face a weak commercial case.
Is oxymorphone hydrochloride attractive for pharmaceutical investment?
As a conventional generic, it has limited investment appeal. The stronger opportunities would involve reliable supply, a specialty formulation, an abuse-deterrent platform, or a differentiated delivery system with enforceable intellectual property.
References
- U.S. Food and Drug Administration. (2017, June 8). FDA requests removal of Opana ER for risks related to abuse. https://www.fda.gov
- U.S. Food and Drug Administration. (2018). Determination that Opana ER was withdrawn from sale for reasons of safety or effectiveness. Federal Register. https://www.federalregister.gov
- Endo International plc. (2017). 2016 annual report.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
- U.S. Drug Enforcement Administration. (n.d.). Controlled substances act and opioid manufacturing controls. https://www.deadiversion.usdoj.gov
